- Home
- BIVI vs SNSE Comparison
BIVI vs SNSE Comparison
Compare BIVI & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- SNSE
- Stock Information
- Founded
- BIVI 2013
- SNSE 2005
- Country
- BIVI United States
- SNSE United States
- Employees
- BIVI N/A
- SNSE N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- SNSE Health Care
- Exchange
- BIVI Nasdaq
- SNSE Nasdaq
- Market Cap
- BIVI 11.9M
- SNSE 10.5M
- IPO Year
- BIVI N/A
- SNSE 2021
- Fundamental
- Price
- BIVI $1.87
- SNSE $8.90
- Analyst Decision
- BIVI
- SNSE Strong Buy
- Analyst Count
- BIVI 0
- SNSE 4
- Target Price
- BIVI N/A
- SNSE $72.50
- AVG Volume (30 Days)
- BIVI 316.9K
- SNSE 10.7K
- Earning Date
- BIVI 11-12-2025
- SNSE 08-05-2025
- Dividend Yield
- BIVI N/A
- SNSE N/A
- EPS Growth
- BIVI N/A
- SNSE N/A
- EPS
- BIVI N/A
- SNSE N/A
- Revenue
- BIVI N/A
- SNSE N/A
- Revenue This Year
- BIVI N/A
- SNSE N/A
- Revenue Next Year
- BIVI N/A
- SNSE N/A
- P/E Ratio
- BIVI N/A
- SNSE N/A
- Revenue Growth
- BIVI N/A
- SNSE N/A
- 52 Week Low
- BIVI $1.42
- SNSE $5.00
- 52 Week High
- BIVI $75.00
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- BIVI 33.55
- SNSE 56.27
- Support Level
- BIVI $1.54
- SNSE $7.93
- Resistance Level
- BIVI $1.68
- SNSE $9.50
- Average True Range (ATR)
- BIVI 0.14
- SNSE 0.58
- MACD
- BIVI 0.26
- SNSE 0.08
- Stochastic Oscillator
- BIVI 73.77
- SNSE 68.09
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).